Bioxcel Therapeutics Inc (BTAI)

BioXcel Therapeutics Stock (BTAI) dropped by 23.41% from $5.51 to $4.22 in the trading on Tuesday November 14, 2023. The reason why BTAI stock down today isnclude

• Weak third-quarter results: The biopharmaceutical company posted a loss of $50.5 million, or $1.72 a share, compared with $41.8 million, or $1.49 a share, in the same quarter a year ago. Analysts had been expecting a loss of $1.27 a share. Revenue of $341,000 missed analyst projections for $600,000
• Regulators' recommendation: BioXcel said that it is aligned with the U.S. Food and Drug Administration's recommendation for the Phase 3 trial of Igalmi as a treatment of agitation in bipolar disorders or schizophrenia to be conducted in the at-home setting.

BioXcel Therapeutics (BTAI) stock is plummeting 41.5% from $7.40 to $4.33 Monday. BioXcel published its second-quarter results before the market opened this morning and paired the release with news of a major restructuring initiative.

https://www.fool.com/investing/2023/08/14/why-bioxcel-therapeutics-stock-is-getting-crushed/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

BioXcel's stock price fell 7.94% from $10.33 to $9.51 on the news that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired the company's securities.

https://www.globenewswire.com/en/news-release/2023/07/26/2711219/32719/en/BioXcel-Therapeutics-Inc-Investors-Contact-Robbins-LLP-if-You-Incurred-Significant-Losses-in-BTAI.html

BioXcel shares plummeted 63.8% from $17.67 to $6.39 after revealing a fraud investigation at its biggest study site.

https://www.investors.com/news/technology/btai-stock-ceo-vimal-mehta-says-this-alzheimers-news-is-a-huge-win-for-society/?src=A00220

Shares of BioXcel Therapeutics (BTAI) were down 25.5% from $25.93 to $19.32 on Thursday after the biotech company released the first part of a phase 3 trial for the therapy BXCL501 (dexmedetomidine) to treat acute agitation in bipolar disorders or schizophrenia.

https://www.fool.com/investing/2023/05/25/why-shares-of-bioxcel-therapeutics-are-dropping-th/?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article

Shares of BioXcel Therapeutics (BTAI) declined 5.35% from $21.48 to $20.33 after announcing that it has confidentially submitted a draft registration statement relating to the proposed initial public offering of its common stock following its conversion into a corporation.

https://finance.yahoo.com/news/onkosxcel-therapeutics-announces-confidential-submission-201500018.html

BioXcel shares plummeted 15.9% from $24.56 to $20.66 regarding the Q4 2022 Earnings Call.

https://finance.yahoo.com/news/q4-2022-bioxcel-therapeutics-inc-073220029.html

BioXcel Therapeutics (BTAI) dipped 13.4% from $28.36 to $24.56 after issuing its financial results for the fourth quarter and full year ended Dec. 31, 2022 and provided an update on key strategic initiatives.

https://finance.yahoo.com/news/bioxcel-therapeutics-reports-fourth-quarter-120000852.html